Practice of paper-free whole blood collection system in constructing intelligent blood station / 中国输血杂志

【Objective】 To establish a paper-free system of the total whole blood donation flow in constructing intelligent blood stations, and build digitalized whole blood donation system for practice. 【Methods】 A paper-free whole blood collection system was constructed through information process reforming, system frame designing and data network transportation constructing, and was applied in various blood donation scenario. 【Results】 Fixed blood collection sites carried out 49 063 donations via paper-free information system from November 2022 to July 2023, and 24 822 donations( group blood donation) were conducted via paper-free system from April to July 2022. Compared with the traditional paper-based model, paper-free system is safer, more standardized and more convenient, effectively enhancing the experience of blood donors. 【Conclusion】 The construction of paper-free whole blood collection system effectively enhances the experience of blood donors, improves the safety, accuracy, traceability of the data, and has good social value and economic value, which is worth popularizing.

Causes of blood donor deferral in primary blood screening, Hangzhou / 中国输血杂志

【Objective】 To investigate the deferral causes of voluntary blood donors in primary blood screening in Hangzhou, so as to take steps to reduce the deferral rate. 【Methods】 The causes of donor deferral in 8 blood donation sites in Hangzhou from January 2019 to December 2020 was statistically analyzed. 【Results】 A total of 103 325 donors(49 335 in 2019, 53 990 in 2020)were registered in 8 blood donation sites in Hangzhou From 2019 to 2020, among which 87 435 (44 462 in 2019, 42 973 in 2020)were successfully donated, and 15 890 (4 873 in 2019, 11 017 in 2020) were deferred, with a deferral rate of 15.38%(9.88% in 2019, 20.41% in 2020). The main reasons leading to donation deferral were Alt, medical history and lipemic blood. Significant differences were noticed in deferral items as medical history, HBsAg, TP, ALT and lipemic blood by gender and donation history, and not in Hb by gender. 【Conclusion】 Promoted publicity, specified primary blood screening, especially the pre-donationTP detection can effectively reduce the proportion of high-risk blood donors, cut down blood deferral rate, thus avoiding the waste of blood resources and balancing blood supply and demand.

Sequence analysis of a novel HLA-B * 9534 allele and establishment of group specific primers polymerase chain reaction method / 中华微生物学和免疫学杂志

Objective To analyze the molecular genetic basis of novel allele HLA-B * 9534 and establish the allele group specific primer PCR method. Methods Genomic DNA was extracted from whole blood by commercial DNA extraction kit. The HLA-B exons 1 to 8 coding sequences of the proband were am-plified by PCR and the amplification product was purified with double enzymes digestion and both strands of exons 2, 3 and 4 were sequenced. The exon 2-4 amplification of the HLA-B * 9534 was performed with al-lele group specific primers PCR and the PCR product was directly sequenced for exon 2 to 4. Results The proband has two HLA-B alleles. The result was assigned for HLA-B * 1518 and B * 4601 combination with a mismatch in 593A/G heterozygote by DNA sequencing of exon 2 to 4 with loci primers. After separating the two alleles of the proband with allele group specific primers polymerase chain reaction method, HLA-B * 4601 and HLA-B * 9534 alleles were identified after sequencing. The HLA-B * 9534 is identical to HLA-B * 1518 except for one nucleotide substitutions in exon 3 at position 593 A→G, this results in amino acid substitution at cedon 174 from Asn to Ser. The sequences of the novel allele have been submitted to GenBank (EU046491) and the allele has been officially nominated by the WHO Nomenclature Committee. Conclusion Identification of a novel HLA-B * 9534 allele and allele group specific primer PCR for HLA-B * 9534 was re-liable.

Sequence analysis and identification of two novel HLA alleles HLA-B*9536 and HLA-B*4612 / 中华医学遗传学杂志

<p><b>OBJECTIVE</b>To identify two novel HLA alleles HLA-B*9536 and B*4612, in an individual.</p><p><b>METHODS</b>DNA was extracted from whole blood by Invitrogen DNA extraction kit. The amplification for HLA-B exons 2-4 of the proband was performed separately with allele group specific primers and the PCR products were directly sequenced for exons 2-4 in both direction.</p><p><b>RESULTS</b>There were two novel HLA-B alleles in the proband. The sequences of the two alleles have been submitted to GenBank (EU081878 and EU081879). The two alleles have been officially named as B*9536 and B*4612 by the WHO Nomenclature Committee. The sequence of exons 2-4 of HLA-B*9536 showed one nucleotide difference in exon 3 at position 544 (G to A) comparing with the closest allele B*1505, which resulted in an amino acid change from Ala to Thr at codon 158. In the HLA-B*4612 allele, there was one nucleotide change in exon 3 at position 363 (G to A), when compared to the closest allele B*4601, which lead to an amino acid change from Arg to Ser at codon 97.</p><p><b>CONCLUSION</b>Two novel HLA-B alleles were identified in one individual and have been officially named by the WHO Nomenclature Committee.</p>